Clinical Trials › Cancer Clinical Trial › Multiple Myeloma › (CIRB) Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Print
A A A

COVID-19 and protecting your health ›

(CIRB) Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Protocol Number: ECOG-E1A11

NCT Number: NCT01863550

Condition/Disease: Cancer - Multiple Myeloma

Principal Investigator: Elizabeth A Brem

Status: Open

Treatment: Treatment

Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide, Velcade

Phase: III

Age Group: Adult

Scope: Local

Learn More:
For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.